Biogen ($BIIB) podcast mentions
Per Ticker.id: 11 Biogen ($BIIB) mentions across 2 podcasts (30 days) — timestamped, verifiable quotes, updated 2026-09-19.
Biogen, for example, has a recent Alzheimer's drug that was just approved by the FDA within the past week or so. Average annual tab is going to predict it to be $56,000 per patient. 3 of the FDA's scientific advisors quit over the approval. It's really not been reliably shown to benefit patients. And the cost-effective price for that medication was judged by an independent group called ICER. The more reasonable price wouldn't be $56,000, it'd be more like $8,300. And we spend so much more than any other country per capita on healthcare. And we just don't get the kinds of outcomes that we need to. And we don't focus the resources on the public health problems and on the poverty problems that lead so many Americans to have very serious health problems. And in some ways, it gets to that point on the index card.
Harold Pollack · People I (Mostly) Admire · 40. Harold Pollack on Why Managing Your Money is as Easy as Taking Out the Garbage · 2026-09-19Plus, shares of Novartis notching big declines this week, following following 3 drug trial setbacks. We will discuss exclusively with CEO Vas Narasimhan. And then here with me in Boston, Biogen CEO Christopher Wiebecker will discuss the biotech's experimental Alzheimer's drug and its current product pipeline.
Sarah Eisen · Squawk on the Street · 11AM Hour: Exclusive Interviews with the CEOs of Biogen, Novartis & Visa 9/9/26 · 2026-09-09Yes, I am here, Carl, today at the Wells Fargo 2026 Healthcare Conference in Boston. And joining me now for CNBC exclusive is Biogen CEO Chris Wiebacher. It's great to have you. We don't get to talk to you very often.
Sarah Eisen · Squawk on the Street · 11AM Hour: Exclusive Interviews with the CEOs of Biogen, Novartis & Visa 9/9/26 · 2026-09-09So we've been working on our pipeline now for a number of years, and I think we're really at about that inflection point where I think we're going to be on a path to sustainable revenue growth. We've got 10 Phase 3 programs that could now start to read out as early as next quarter with product registration approval submissions as early as next year. We could have 5 new molecules coming to market that could treat up to 8 different diseases. So it's pretty exciting times at Biogen.
Chris Wiebecker · Squawk on the Street · 11AM Hour: Exclusive Interviews with the CEOs of Biogen, Novartis & Visa 9/9/26 · 2026-09-09You asked me to choose between my children. I think each of them, you know, Biogen has been this company that has been dedicated to breakthrough medicine. So we've got rare kidney disease, we've got a new treatment for lupus, we've got a first-time treatment for antibody-mediated rejection of kidney transplant. There's an exciting new medicine coming along. There was just a European Epilepsy Congress, a drug called Zorvannersen for Dravet syndrome. It's a disease that really affects small children. They have so many epileptic seizures, it affects their mental development. Next generation for spinal muscular atrophy. So all of these are extremely important new medicines for patients.
Chris Wiebecker · Squawk on the Street · 11AM Hour: Exclusive Interviews with the CEOs of Biogen, Novartis & Visa 9/9/26 · 2026-09-09So I think where we are now, as I was saying earlier, we're at a point of real inflection for growth. We have all of these new products to launch over the coming years. So we're not really looking actively for acquisitions. We might be opportunistic. What we're really doing is now focused on early stage development and research. We're actually already building the growth platform for Biogen for the 2030s.
Chris Wiebecker · Squawk on the Street · 11AM Hour: Exclusive Interviews with the CEOs of Biogen, Novartis & Visa 9/9/26 · 2026-09-09Good to see you from Biogen. Carl, back over to you.
Sarah Eisen · Squawk on the Street · 11AM Hour: Exclusive Interviews with the CEOs of Biogen, Novartis & Visa 9/9/26 · 2026-09-09Good Wednesday morning and welcome to Squawk on the Street. I'm Sarah Izen with Carl Quintanilla and David Faber live from the Wells Fargo Healthcare Conference today in Boston. More than 300 companies participating, 2,000 people attending here. In just a few minutes, I will speak with the host, Wells Fargo CEO Charlie Scharf, about his business, the economy, and much more. Next hour, CEO of Biogen joins us for a rare interview on the company's drug pipeline and rising healthcare costs.
Sarah Eisen · Squawk on the Street · 10AM Hour: Wells Fargo, Chime & Charter CEOs 9/9/26 · 2026-09-09Yes, we've got dueling conferences here, David, with you in tech and me in healthcare. Still to come this morning for me, the CEO of Biogen is with us. Live from Wells Fargo 2026 Healthcare Conference. More on the company's M&A strategy, the outlook for new drug development. Plus later, do not miss the CEO of Novartis. The stock coming off its worst day ever after some disappointing drug trial data. The CEO will join us to discuss. Don't go anywhere.
Sarah Eisen · Squawk on the Street · 10AM Hour: Wells Fargo, Chime & Charter CEOs 9/9/26 · 2026-09-09One of them went like 3 hours. Yeah. Yeah. Thursday. Okay. Thank you, Christina. Christina Parts and Everless. Big show still to come, including the CEO of Charter with David from Goldman's COPIA conference on its acquisition of Cox, plus the growth in broadband and mobile. A lot to discuss there. And then later, do not miss the CEO of Biogen. He'll be here with me at the Wells Fargo Healthcare Conference. We'll talk the M&A pipeline and much more.
Sarah Eisen · Squawk on the Street · 10AM Hour: Wells Fargo, Chime & Charter CEOs 9/9/26 · 2026-09-09Okay. Thank you. We're going to talk more about this. Thank you, Annika. Annika Kim, tomorrow, live coverage from the Wells Fargo Healthcare Conference in Boston where we can talk about this issue of, of M&A and, you know, some of these, these riskier drugs and developments. We'll have the CEO of Wells Fargo, CEO of Biogen, and more right here on Squawk on the Street. Coming up after the break, we'll discuss what to expect from Apple's big launch event tomorrow. We're back in just a moment. Welcome back. Apple hosting a launch event tomorrow. Mackenzie Segalas joins us with what to expect. Mackenzie.
Sarah Eisen · Squawk on the Street · 11AM Hour: TD Bank's Jeff Solomon, Novartis Shares Plunge & Oil Prices on the Rise 9/8/26 · 2026-09-08Okay, Brandon, thank you. Still to come, it's one of the biggest tech and telecom events of the year. Goldman Sachs's Communicopia conference kicks off today. We're going to talk to one of the firm's top analysts about what to expect. And speaking of conferences, it's the season. Tomorrow we'll be live from Wells Fargo's healthcare conference in Boston, where I'll be sitting down with the CEO of Wells Fargo, Charlie Scharf, the CEO of Biogen as well. That all begins tomorrow, 10 a.m. Eastern. Stay with us. Dow under some pressure here, down about 650 points right now, kicking off the week in the red. We have higher oil prices. We have higher Treasury yields. At least the 2-year, the 10-year are sharply higher. Look, we'll get more inflation data later in the week with wholesale inflation on Thursday, Friday, the Consumer Price Inflation report. And the focus remains on the tensions in Iran, which are only going in one direction, which is escalation right now. And word that the Houthis, an Iranian proxy terrorist group, is firing at Saudi energy infrastructure. None of that helps. And that's why you're seeing the pressure on stocks and rising oil prices. Look at what's green. Chevron, of course, benefits from higher oil prices. And then a few of the staples like a Coca-Cola and a McDonald's. Carl.
Sarah Eisen · Squawk on the Street · 10AM Hour: Stocks Sink as Oil Spikes, Risks for the AI Boom, Qualcomm Inks Data Center Deal with Amazon 9/8/26 · 2026-09-08It's the opposite. The advance-decline line is making a record high. People are making money in biotechs. People are making money in retailers and making money in health insurance companies, making money in REITs. It's, it's, it's oil stocks. It's a literal opposite of 1999. I know it didn't feel that way for a lot of last year. Excuse me, for a lot of 2024. When it felt like it was all Mag7 and that was legitimate to talk about that concept. But that was just the first phase of the AI bull market. Now we're like in the third phase and you've got companies involved in the AI trade that are going up. You have companies that have nothing to do with the AI trade also going up. Take a look at J.B. Hunt. Take a look at, uh, Insight, which I talked about on the air today on TV. Biogen Idec, or we don't call it that anymore, Biogen Inc. Um, they have nothing to do with it at all, and they're going straight up and to the right. We talked about on the show Casey's General Store. It's, it's fucking gas station pizza in Nebraska. There are so many of those hundreds of those that I can off the top of my head. This idea that the 1999— oh, it's all— now I am sympathetic to people saying the rally in the financials is based on AI and its concentration, and it's 1999-esque. That part I will grant you. When I looked at the earnings reports from Morgan Stanley and read their commentary after, there are $10 trillion in assets and they specifically on the wealth side, they added 9— I forget the number on the wealth side. It was some obscene number for the quarter. And they were saying, yeah, this is companies going public and we have all their shareholders as, as wealth management clients. And they said there's going to be more of this. So I am sympathetic to the argument that a lot of the market is rallying on the AI theme. I would not say that's not true.. But I would just make the point, it's not one narrow group of stocks. It is literally the opposite.
Josh Brown · The Compound and Friends · Midsummer’s Melt-Up, Robinhood, SpaceX and Palantir Report, Chips Rip, Leopold’s Margin Call · 2026-08-04Meanwhile, Biogen gutted the pipeline it bought for $5.6 billion, European regulators are moving to pull Amgen's Tavnéos off the market entirely, and Lilly surged 7% heading straight into Monday's Orforglipron decision. Friday delivered.
Speaker B · The Pharma Closeout _ Daily Pharmaceutical & Biotech News in 15 Minutes · Jun 26, 2026 | FDA Approves Viridian for Thyroid Eye Disease; Merck KGaA's $11.3B Bio-Techne Deal · 2026-06-27Meanwhile, Biogen is showing exactly what it bought Apellis for. And what it didn't. After closing that $5.6 billion acquisition, Biogen is cutting most of Appellis's pipeline programs. Investors approved of the discipline. Biogen shares up nearly 7% on the day.
Speaker A · The Pharma Closeout _ Daily Pharmaceutical & Biotech News in 15 Minutes · Jun 26, 2026 | FDA Approves Viridian for Thyroid Eye Disease; Merck KGaA's $11.3B Bio-Techne Deal · 2026-06-27